Accrued amount for legal settlements and loss contingencies

$ 4,077

€ 60.5

$ 2,710

The expenses in the third quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, as well as an estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation.

Legal Settlements and Loss Contingencies - Additional Information (Detail) € in Millions, $ in Millions		3 Months Ended		9 Months Ended
	Jun. 02, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Legal settlements and loss contingencies, expense	$ 420	$ 195	$ 3	$ 2,048	$ 113
Accrued amount for legal settlements and loss contingencies		$ 4,077		$ 4,077		€ 60.5	$ 2,710
Restructuring expense and income					The expense in the first nine months of 2021 was mainly due to the provision recorded for the carvedilol patent litigation.
Settlement On Account Of Product Liability [Member]
Loss Contingencies [Line Items]
Restructuring expense and income		The expenses in the third quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, as well as an estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation.